Teva Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Teva Pharma (TEVA) PT Lowered to $9 at Cowen
August 7, 2019 11:14 AM EDTCowen analyst Ken Cacciatore lowered the price target on Teva Pharma (NYSE: TEVA) to $9.00 (from $16.00) while maintaining a Market Perform rating.
The analyst commented, "Teva continues to perform as well as can be expected, with good cost reductions while still investing in Austedo & Ajovy.... More
Teva Pharma (TEVA) Tops Q2 EPS by 3c, Reaffirms Guidance
August 7, 2019 7:01 AM EDTTeva Pharma (NYSE: TEVA) reported Q2 EPS of $0.60, $0.03 better than the analyst estimate of $0.57. Revenue for the quarter came in at $4.3 billion versus the consensus estimate of $4.25 billion.
Full year 2019 revenues and EPS guidance reaffirmedFor earnings history and earnings-related data on Teva Pharma (TEVA) click here.
... More